Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course linezolid-containing therapy for HIV-associated pulmonary tuberculosis
ChiCTR2500103477Phase 4Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of linezolid, isoniazid, rifampicin, pyrazinamide and ethambutol in Tuberculosis (TB) and human immunodeficiency virus infection (HIV), sponsored by Beijing YouAn Hospital. Primary endpoints: Composite unfavorable outcome at 12 months and Mortality rate at 12 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
linezolidisoniazidrifampicinpyrazinamideethambutol
03
Conditions
Tuberculosis (TB)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2500103477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103477.